KYMERA THERAPEUTICS, INC. (KYMR) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $8.00K; Additional Paid in Capital, Common StockUSD $2.71B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-7.16M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $8.00K; Additional Paid in Capital, Common StockUSD $2.68B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-4.19M.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $8.00K; Additional Paid in Capital, Common StockUSD $2.64B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $1.80M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $7.00K; Additional Paid in Capital, Common StockUSD $1.92B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $1.50M.
KYMERA THERAPEUTICS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $8.00K | $2.71B | $-7.16M | $-1.20B | $1.51B | 3 month · $18.94M 6 month · $34.95M |
| 2026-03-31 | $0.00 | $8.00K | $2.68B | $-4.19M | $-1.14B | $1.54B | 3 month · $16.01M |
| 2025-12-31 | $0.00 | $8.00K | $2.64B | $1.80M | $-1.07B | $1.58B | 12 month · $59.90M |
| 2025-09-30 | $0.00 | $7.00K | $1.92B | $1.50M | $-978.98M | $946.26M | 3 month · $15.80M 9 month · $45.45M |
| 2025-06-30 | $0.00 | $7.00K | $1.87B | $279.00K | $-896.80M | $971.48M | 3 month · $15.41M 6 month · $29.65M |
| 2025-03-31 | (m) | $7.00K | $1.61B | $-58.00K | $-820.19M | $786.23M | 3 month · $14.23M |
| 2024-12-31 | $0.00 | $7.00K | $1.59B | $-1.49M | $-754.61M | $835.62M | 12 month · $55.01M |
| 2024-09-30 | (m) | $7.00K | $1.57B | $1.93M | $-683.86M | $892.93M | 3 month · $14.90M 9 month · $41.21M |
| 2024-06-30 | (m) | $6.00K | $1.31B | $-2.10M | $-621.37M | $684.92M | 3 month · $14.34M 6 month · $26.31M |
| 2024-03-31 | (m) | $6.00K | $1.29B | $-1.78M | $-579.31M | $711.20M | 3 month · $11.97M |
| 2023-12-31 | (m) | $6.00K | $926.27M | $-552.00K | $-530.75M | $394.97M | 12 month · $43.12M |
| 2023-09-30 | (m) | $6.00K | $914.36M | $-2.45M | $-516.38M | $395.54M | 3 month · $11.65M 9 month · $32.22M |
| 2023-06-30 | (m) | $6.00K | $902.57M | $-3.63M | $-463.52M | $435.43M | 3 month · $11.18M 6 month · $20.57M |
| 2023-03-31 | (m) | $6.00K | $889.75M | $-3.04M | $-424.72M | $462.00M | 3 month · $9.38M |
| 2022-12-31 | (m) | $6.00K | $878.88M | $-4.95M | $-383.79M | $490.15M | 12 month · $35.48M |
| 2022-09-30 | (m) | $6.00K | $867.72M | $-5.91M | $-348.93M | $512.88M | 3 month · $9.08M 9 month · $26.57M |
| 2022-06-30 | (m) | $5.00K | $707.85M | $-3.98M | $-305.92M | $397.95M | 3 month · $9.62M 6 month · $17.50M |
| 2022-03-31 | (m) | $5.00K | $697.60M | $-3.22M | $-265.67M | $428.72M | 3 month · $7.87M |
| 2021-12-31 | (m) | $5.00K | $689.27M | $-660.00K | $-228.98M | $459.64M | 12 month · $24.97M |
| 2021-09-30 | $0.00 | $5.00K | $678.36M | $-146.00K | $-195.08M | $483.13M | 3 month · $7.40M 9 month · $16.29M |
| 2021-06-30 | (m) | $5.00K | $424.60M | (m) | $-166.50M | $258.10M | 3 month · $5.73M 6 month · $8.90M |
| 2021-03-31 | (m) | $4.00K | $417.10M | $-13.00K | $-141.84M | $275.25M | 3 month · $3.17M |
| 2020-12-31 | (m) | $4.00K | $412.78M | $-128.00K | $-128.76M | $283.89M | 12 month · $5.19M |
| 2020-09-30 | (m) | $4.00K | $410.93M | $-164.00K | $-116.08M | $294.69M | 3 month · $2.33M 9 month · $3.36M |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | $-107.29M | 3 month · $664.00K 6 month · $1.03M |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | $-93.80M | 3 month · $371.00K |
| 2019-12-31 | (m) | (m) | $2.04M | $6.00K | $-76.46M | $-74.41M | 12 month · $1.20M |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | $-63.22M | 3 month · $234.00K 9 month · $899.00K |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | $-52.08M | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | $-34.44M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |